GYRE
NASDAQ · Biotechnology
Gyre Therapeutics Inc
$7.47
+0.40 (+5.66%)
Financial Highlights (FY 2026)
Revenue
110.34M
Net Income
4.76M
Gross Margin
95.3%
Profit Margin
4.3%
Rev Growth
+428.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 95.3% | 31.7% | 31.7% | 31.7% |
| Operating Margin | 9.8% | -10.8% | -10.0% | -10.6% |
| Profit Margin | 4.3% | -15.0% | -12.8% | -11.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 110.34M | 231.94M | 230.03M | 258.04M |
| Gross Profit | 105.21M | 73.42M | 72.82M | 81.68M |
| Operating Income | 10.87M | -25,032,546 | -23,113,950 | -27,310,626 |
| Net Income | 4.76M | -34,891,358 | -29,454,556 | -30,205,686 |
| Gross Margin | 95.3% | 31.7% | 31.7% | 31.7% |
| Operating Margin | 9.8% | -10.8% | -10.0% | -10.6% |
| Profit Margin | 4.3% | -15.0% | -12.8% | -11.7% |
| Rev Growth | +428.5% | -3.5% | +14.1% | +6.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 112.30M | 100.36M | 97.13M |
| Total Equity | — | 448.31M | 485.41M | 472.92M |
| D/E Ratio | — | 0.25 | 0.21 | 0.21 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 14.36M | -32,635,653 | -32,852,234 | -35,942,077 |
| Free Cash Flow | — | -26,269,864 | -27,800,469 | -23,210,699 |